David Domzalski Vyne Therapeutics Inc. (VYNE) insider trading activity

David Domzalski is PRESIDENT AND CEO of VYNE Therapeutics Inc.. Currently has a direct ownership of 500,597 shares of VYNE, which is worth approximately $1.59 Million. The most recent transaction as insider was on Nov 30, 2024, when has been sold 3,901 shares (Common Stock) at a price of $2.1 per share, resulting in proceeds of $8,192. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 501K

0.59% 3M change

84.61% 12M change

Total Value Held $1.59 Million

David Domzalski Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 30 2024	BUY Grant, award, or other acquisition	$8,192 $2.1 p/Share	3,901 Added 0.77%	500,597 Common Stock
Sep 30 2024	SELL Payment of exercise price or tax liability	$1,287 $1.88 p/Share	685 Reduced 0.14%	496,696 Common Stock
Jul 01 2024	SELL Payment of exercise price or tax liability	$1,795 $1.92 p/Share	935 Reduced 0.19%	497,654 Common Stock
May 31 2024	BUY Grant, award, or other acquisition	$9,566 $2.16 p/Share	4,429 Added 0.88%	498,589 Common Stock
Apr 01 2024	SELL Payment of exercise price or tax liability	$3,092 $3.08 p/Share	1,004 Reduced 0.2%	494,160 Common Stock
Jan 02 2024	SELL Payment of exercise price or tax liability	$2,289 $2.28 p/Share	1,004 Reduced 0.2%	495,164 Common Stock
Jan 01 2024	BUY Grant, award, or other acquisition	-	225,000 Added 31.2%	496,168 Common Stock
Dec 13 2023	BUY Grant, award, or other acquisition	-	225,000 Added 45.35%	271,168 Common Stock
Nov 30 2023	BUY Grant, award, or other acquisition	$6,418 $2.81 p/Share	2,284 Added 4.71%	46,168 Common Stock
Oct 02 2023	SELL Payment of exercise price or tax liability	$32,742 $3.83 p/Share	8,549 Reduced 16.3%	43,884 Common Stock
Jun 30 2023	SELL Payment of exercise price or tax liability	$4,022 $4.1 p/Share	981 Reduced 1.84%	52,433 Common Stock
May 31 2023	BUY Grant, award, or other acquisition	$9,570 $3.46 p/Share	2,766 Added 4.92%	53,414 Common Stock
Mar 31 2023	SELL Payment of exercise price or tax liability	$8,420 $3.08 p/Share	2,734 Reduced 5.12%	50,648 Common Stock
Dec 31 2022	SELL Payment of exercise price or tax liability	$1,602 $0.15 p/Share	10,685 Reduced 0.99%	1,064,290 Common Stock
Nov 30 2022	BUY Grant, award, or other acquisition	$6,941 $0.2 p/Share	34,705 Added 3.13%	1,074,975 Common Stock
Sep 30 2022	SELL Payment of exercise price or tax liability	$2,350 $0.22 p/Share	10,683 Reduced 1.02%	1,040,270 Common Stock
Jun 30 2022	SELL Payment of exercise price or tax liability	$4,166 $0.39 p/Share	10,683 Reduced 1.01%	1,050,953 Common Stock
May 31 2022	BUY Grant, award, or other acquisition	$4,160 $0.35 p/Share	11,887 Added 1.11%	1,061,636 Common Stock
Mar 31 2022	SELL Payment of exercise price or tax liability	$15,071 $0.65 p/Share	23,186 Reduced 2.16%	1,049,749 Common Stock
Mar 17 2022	BUY Grant, award, or other acquisition	-	312,302 Added 22.55%	1,072,935 Common Stock
Dec 31 2021	SELL Payment of exercise price or tax liability	$7,025 $1.02 p/Share	6,887 Reduced 0.9%	760,633 Common Stock
Nov 30 2021	BUY Grant, award, or other acquisition	$4,140 $0.88 p/Share	4,705 Added 0.61%	767,520 Common Stock
Sep 30 2021	SELL Payment of exercise price or tax liability	$18,203 $1.39 p/Share	13,096 Reduced 1.69%	762,815 Common Stock
Sep 02 2021	BUY Grant, award, or other acquisition	-	320,312 Added 29.22%	775,911 Common Stock
Jun 30 2021	SELL Payment of exercise price or tax liability	$66,195 $3.51 p/Share	18,859 Reduced 3.97%	455,599 Common Stock

David Domzalski

PRESIDENT AND CEO

Bridgewater, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VYNE shares.

Notify only if

Value

Insider Trading

Get notified when an Vyne Therapeutics Inc. insider buys or sells VYNE shares.

Notify only if

Operation

Value

Type

News

Receive news related to VYNE Therapeutics Inc.

Track Activities on VYNE

Account